A general process for the development of peptide-based immunoassays for monoclonal antibodies. - Wikidata - wikimedia - TriplyDB

A general process for the development of peptide-based immunoassays for monoclonal antibodies.

A general process for the development of peptide-based immunoassays for monoclonal antibodies.

http://www.wikidata.org/entity/Q33525284

about

Interferometric methods for label-free molecular interaction studies EGFR-binding peptide: a patent evaluation of WO2014002836.Selection of DNA nanoparticles with preferential binding to aggregated protein target.LC-MS/MS Validation Analysis of Trastuzumab Using dSIL Approach for Evaluating Pharmacokinetics.Identification and characterization of two linear epitope motifs in hepatitis E virus ORF2 protein.Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms.Identification of Peptide Mimotope Ligands for Natalizumab

P2860

Q35050015-A00ACA2C-38B0-417D-8A42-61E53E8DCF85 Q35433987-4CF4104C-FA45-4BD3-B1B9-9667A1091A8A Q36959018-E8ECBDE2-742F-455A-9C84-C76B4B8489A5 Q39202214-7A0C1D08-8491-4F15-8B93-3F6105DF3653 Q41928684-140343E2-56A8-4A69-8D25-9DEAB5D7DB0F Q43249169-3B220B7B-9E4E-47D8-AC65-BF96666BD164 Q56876832-58A911B4-86AF-4586-90E2-B394C0FAB249

P2860

A general process for the development of peptide-based immunoassays for monoclonal antibodies.

http://www.wikidata.org/entity/Q33525284

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A general process for the deve ...... ays for monoclonal antibodies.

@ast

A general process for the deve ...... ays for monoclonal antibodies.

@en

A general process for the deve ...... ays for monoclonal antibodies.

@nl

type

label

A general process for the deve ...... ays for monoclonal antibodies.

@ast

A general process for the deve ...... ays for monoclonal antibodies.

@en

A general process for the deve ...... ays for monoclonal antibodies.

@nl

prefLabel

A general process for the deve ...... ays for monoclonal antibodies.

@ast

A general process for the deve ...... ays for monoclonal antibodies.

@en

A general process for the deve ...... ays for monoclonal antibodies.

@nl

P1433

Q33525284-64278511-B80C-4678-BA3D-73B7CD0AAAE1

P1476

Q33525284-E602B50C-D94B-4D1C-BDAA-21963B8D9594

P2093

Q33525284-14FA94F5-6DEB-450F-B823-8687D4FFB4E5

Q33525284-239A157F-46FB-4ED3-A32E-5DF9DCD0DE9A

Q33525284-626C80F4-1FA0-44A2-9FA9-D31AFC31CBD8

Q33525284-6CCACDEB-6549-40E2-AB0B-2AF85E666CA4

Q33525284-7D23F0E7-9C80-42D2-A119-8E1ECB947E36

Q33525284-CAB7CCAE-AE79-47CA-A075-A1D27EC10E38

P2860

Q33525284-0E4075A2-2916-4B4A-A6B2-7670BC2E69E4

Q33525284-1A17D1BC-5355-411B-8C5A-4EE8F1DA59B8

Q33525284-1D5DDB79-5D2F-40C7-9BB2-3C962A58A7E9

Q33525284-2770B96A-86F6-4B9C-AD88-2F3893528D53

Q33525284-418EC956-0D73-42DB-89AC-92383C1CF461

Q33525284-41D57EC1-8A12-461C-81F0-F88FCBD07DE7

Q33525284-4A2DBD22-12B4-4135-B934-ED8E4511B1AA

Q33525284-8FDFE792-43D7-4D30-BAEC-0E6E2D1E0353

Q33525284-A494AA34-6604-4045-97FA-C13FF024865A

Q33525284-B41BBE91-F19D-486E-88D7-7F30667F6270

P2888

Q33525284-03354307-2504-4E05-8F8C-68E6BEC13277

P304

Q33525284-EA51761C-4067-4EEE-BA22-093EC39B8AD4

P31

Q33525284-32196DA5-614B-4574-B999-0A171796A051

P356

Q33525284-25699717-7B22-441B-B648-DC83A293CD26

P433

Q33525284-19D2FF54-9573-4075-8D48-54738200A033

P478

Q33525284-12B0E325-AB2C-4569-A90F-22A74D2D86B0

P577

Q33525284-A7606E97-C224-4A02-855A-D418E433E4E9

P5875

Q33525284-64CFA08D-EE21-4A3E-8964-227780267E29

P6179

Q33525284-3C10D279-7059-4ECF-AB03-58F03F3BCEEA

P698

Q33525284-1D14219E-6981-47F4-914D-E97E36625C3E

P921

Q33525284-800C5D9C-B24E-4139-A026-AA9E18A1D806

P932

Q33525284-DEF57461-B4C7-454E-BDCE-8D1519C3CAC1

P356

S00280-009-1240-1

P1433

Cancer Chemotherapy and Pharmacology

P1476

A general process for the deve ...... ays for monoclonal antibodies.

@en

P2093

Ana B Sanchez

http://www.w3.org/2001/XMLSchema#string

Andrew C Kummel

http://www.w3.org/2001/XMLSchema#string

Bradley T Messmer

http://www.w3.org/2001/XMLSchema#string

Rhanika Dema-Ala

http://www.w3.org/2001/XMLSchema#string

Tammy Nguyen

http://www.w3.org/2001/XMLSchema#string

Thomas J Kipps

http://www.w3.org/2001/XMLSchema#string

P2860

Convergent solutions to binding at a protein-protein interface

Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas.

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

Two human neonatal IgM antibodies encoded by different variable-region genes bind the same linear peptide: evidence for a stereotyped repertoire of epitope recognition.

Evaluation of resins for on-bead screening: a study of papain and chymotrypsin specificity using PEGA-bound combinatorial peptide libraries.

A new hybrid resin for stepwise screening of peptide libraries combined with single bead Edman sequencing.

Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy.

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

Cytokine quantitation: technologies and applications.

Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein.

P2888

s00280-009-1240-1

P304

919-925

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-009-1240-1

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41089668

http://www.w3.org/2001/XMLSchema#string

P6179

1038153113

http://www.w3.org/2001/XMLSchema#string

P698

20087593

http://www.w3.org/2001/XMLSchema#string

P921

P932

2921063

http://www.w3.org/2001/XMLSchema#string